Rayan Kabirian

Rayan Kabirian

Auto-generated profile, based on publicly available information

Rayan Kabirian

Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer Institut Curie, Université Paris Cité Paris France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ACAurélie Cabannes‐Hamy
Aurélie Cabannes‐Hamy
RKRayan Kabirian
Rayan Kabirian
FJFloriane Jochum
Floriane Jochum
KBKevin Bihan
Kevin Bihan
EDElise Dumas
Elise Dumas
PGPaul Gougis
Paul Gougis
Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have greatly improved the survival of patients with chronic myeloid leukemia (CML), and their teratogenicity appears as an important factor for individuals of childbearing potential. This study aims to investigate pregnancy and fetal/newborn adverse outcomes resulting from exposure to BCR::ABL1‐TKIs during pregnancy. For this disproportionality analysis, we used the WHO's global VigiBase up to January 2024, and included reports involving pregnancy, antineoplastic treatment during pregnancy, and cancer. The exposure group consisted of reports mentioning BCR::ABL1‐TKIs at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal‐fetal complications in the BCR::ABL1‐TKIs group compared to other anticancer treatments. The analysis included 3,389 reports (TKI = 969; other = 2,420). In the BCR::ABL1‐TKI‐exposed group, the mean age was 28.9 years, and 724 patients (92.2%) were treated for CML. BCR::ABL1‐TKIs were mainly imatinib (n = 642, 66.3%), nilotinib (n = 218, 22.5%), and dasatinib (n = 127, 13.1%) reported without other non‐TKI anticancer agents(92.3%). Compared to other anticancer drugs, overreported outcomes with TKIs included hydrops fetalis (ROR = 13 [95%CI = 1.5–110], P = 0.009), polyhydramnios (ROR = 5 [1.3–20], P = 0.02), and threatened preterm labor (ROR = 10 [1.1–90], P = 0.03). When analyzing specific molecule effects, hydrops fetalis (ROR = 27 [5.4–130], P = 0.001) and polyhydramnios (ROR = 13 [3.3–54], P = 0.004) were overreported with dasatinib. In this large cohort of 969 individuals exposed to TKIs during pregnancy, dasatinib use was associated with most BCR::ABL1‐TKI‐specific toxicities and should be avoided during pregnancy. Fewer or no adverse events were overreported with imatinib and nilotinib.

14 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
EDElise Dumas
Elise Dumas
LLLucie Laot
Lucie Laot
FCFlorence Coussy
Florence Coussy
Beatriz Grandal RejoBeatriz Grandal Rejo
Beatriz Grandal Rejo
Eric DaoudEric Daoud
Eric Daoud
AHAnne Sophie Hamy
Anne Sophie Hamy
Background: Breast cancer (BC) is the most frequent cancer and the leading cause of cancer-related death in women. The French National Cancer Institute has created a national cancer cohort to promote cancer research and improve our understanding of cancer using the National Health Data System (SNDS). This cohort amalgamates all cancer sites, with no detailed separate data for early BC. Objectives: We describe the French Early Breast Cancer Cohort (FRESH). Methods: All French women aged 18 years or over, with early-stage BC newly diagnosed between January 1, 2011 and December 31, 2017, treated by surgery and registered in the general health insurance coverage plan were included in the cohort. Patients with suspected locoregional or distant metastases at diagnosis were excluded. BC treatments (surgery, chemotherapy, targeted therapy, radiotherapy, endocrine therapy), and diagnostic procedures (biopsy, cytology, imaging) were extracted from hospital discharge reports, outpatient care notes or pharmacy drug delivery data. BC subtype was inferred from the treatments received. Results: We included 235,368 patients with early BC in the cohort (median age: 60 years). BC subtype distribution was as follows: luminal (80.2%), triple-negative (TNBC, 9.5%); HER2 + (10.3%), or unidentifiable ( n =44,388, 18.9% of the cohort). Most patients underwent radiotherapy ( n =200,685, 85.3%) and endocrine therapy ( n =165,655, 70.4%), and 38.3% ( n =90,252) received chemotherapy. Treatments and care pathways are described. Conclusion: The FRESH Cohort is an unprecedented population-based resource facilitating future large-scale real-life studies aiming to improve care pathways and quality of care for BC patients.

19 August 2024 in Future Oncology
Verified
Journal Article
Open access
RKRayan Kabirian
Rayan Kabirian
OTOlivier Tredan
Olivier Tredan
FMFrederik Marmé
Frederik Marmé
XPXavier Paoletti
Xavier Paoletti
LELauriane Eberst
Lauriane Eberst
ALAlexandra Leary
Alexandra Leary
Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.Clinical Trial Registration: NCT04713514 (ClinicalTrials.gov).

15 July 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
RKRayan Kabirian
Rayan Kabirian
MGMathilde de Saint Ghislain
Mathilde de Saint Ghislain
OSOlivia Le Saux
Olivia Le Saux
LMLaurent Mathiot
Laurent Mathiot
JFJean-Sebastien FRENEL
Jean-Sebastien FRENEL
ALAlexandra Leary
Alexandra Leary

29 July 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RKRayan Kabirian
Rayan Kabirian
FJFloriane Jochum
Floriane Jochum
EDElise Dumas
Elise Dumas
FCFlorence Coussy
Florence Coussy
KBKevin Bihan
Kevin Bihan
PGPaul Gougis
Paul Gougis
Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC) systemic treatments. The exposure group consisted of reports mentioning a BC treatment at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal–fetal complications with the two cornerstone cytotoxic classes, anthracyclines (doxorubicin, epirubicin) and taxanes (docetaxel, paclitaxel), assessed individually vs. other anticancer treatments. Secondary analyses assessed all BC treatments and trimester‐specific risks. Of 3310 pregnancy‐related reports, 1789 involved BC treatments. Median maternal age was 27.4 years (SD 13.8) vs. 29.3 (SD 11.7) in the comparator group. Adverse maternal–fetal outcomes were reported in 998 (55.8%) BC treatment reports vs. 470 (30.9%) in other anticancer treatments. Anthracyclines were associated with neonatal hematologic disorders (ROR = 1.7, 95% CI = 1.1–2.5) and intrauterine growth restriction (IUGR) (ROR = 2.1, 95% CI = 1.7–2.7). Paclitaxel was linked to sensory defects including congenital ear/ocular anomalies (ROR = 5.2, 95% CI = 2.2–12.3); all 8 cases involved platinum co‐exposure (cisplatin: n = 5; carboplatin: n = 3), suggesting a platinum‐mediated mechanism; and to hyperbilirubinemia (ROR = 4.1, 95% CI = 2.0–8.4), and docetaxel to neonatal neurologic disorders (ROR = 3.6, 95% CI = 1.4–9.3). First‐trimester exposure ( n = 26) showed preliminary signals of increased congenital malformation risk, including face (ROR = 13, 95% CI = 2–79), and musculoskeletal malformation (ROR = 8, 95% CI = 1.1–60). This pharmacovigilance study identifies signals of disproportionate reporting of specific maternal and neonatal outcomes with BC treatments; these findings are hypothesis‐generating and require confirmation in prospective registries.

29 August 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
RKRayan Kabirian
Rayan Kabirian
ALAlexandra Leary
Alexandra Leary